Currently, the standard clinical treatment used to slow CKD progression is to block the renin–angiotensin–aldosterone system (RAAS) using angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor type 1 (AT1) antagonists, or direct renin blockers. This evidence concerns the gene AGTR1 and chronic kidney disease.